TrialInternational journal of cancer2016

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

A G Duffy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.